[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478848":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":36,"locations":43,"responsibleParty":61,"collaborators":11,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Fuzhou General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab combined with chemothapy","EXPERIMENTAL",null,[13,14,15,16],"Drug: Tislelizumab","Drug: Albumin paclitaxel","Drug: Nedaplatin","Radiation: radiotherapy",[18,23,27,31],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Tislelizumab","Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks",[9],{"type":19,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"Albumin paclitaxel","Participants will receive Albumin paclitaxel 260 mg\u002Fm2 , day 1 of every 3 weeks",[9],{"type":19,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"Nedaplatin","Participants will receive Nedaplatin 80 mg\u002Fm2 , day 1 of every 3 weeks",[9],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"RADIATION","radiotherapy","50-60Gy\u002F25-30f",[9],[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Fu zhi chao, Doctor of Medicine","CONTACT","13774562945","86","fauster1112@126.com",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Ye zai sheng","RECRUITING","Fuzhou","Fujian","350500","China","CN",{"type":53,"coordinates":54},"Point",[55,56],119.30611,26.06139,{"lat":56,"lon":55},[59],{"name":60,"role":39,"phone":40,"phoneExt":41,"email":42},"Fu zhi chao, doctor",{"type":62,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100478848","phase-2-induction-tislelizumab-combined-with-chemotherapy-followed-by-definitive-chemoradiotherapy-in-the-treatment-of-locally-unresectable-esophageal-squamous-cell-carcinoma-100478848",false,"NCT05515315","Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically confirmed localized ESCC that is suitable for cCRT, including: stage II-IVA (AJCC version 8) inoperable ESCC (medically unfit for surgery or refusing surgical intervention);;\n* Aged 18-70, both sexes;\n* ECOG score 0-1\n* The presence of measurable and\u002For nonmeasurable lesions that met the definition of RECIST1.1;\n* Adequate organ and bone marrow function, meeting the following definitions:\n\n  1. Blood routine (no blood transfusion, no granulocyte colony-stimulating factor \\[G-CSF\\], and no other drugs were used within 14 days before treatment);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;Hemoglobin (HB) ≥9.0 g\u002FdL;Platelet count (PLT) ≥100×109\u002FL;\n  2. Blood biochemistry Creatinine clearance rate ≥60 mL\u002Fmin;Total bilirubin (TBIL) ≤ 1.5×ULN;Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤2.5×ULN;\n* Expected survival time \\> 6 months;\n* Fertile female subjects and male subjects with partners of reproductive age are required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last treatment;\n* Patients who volunteered to participate in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n* A history of fistula caused by primary tumor invasion;\n* Presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites that required repeated drainage or medical intervention (within 2 weeks before randomization);\n* Known intolerance or resistance to chemotherapy specified in the trial protocol;\n* have received any other ESCC antitumor therapy (e.g., therapy targeting PD-1, PD-L1, PD-L2 or other tumor immunotherapy, radiotherapy, targeted therapy, ablation or other systemic or local antitumor therapy);\n* Patients with active autoimmune disease or a history of autoimmune disease that may relapse, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* History of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis and acute lung disease;\n* Severe chronic or active infection (including tuberculosis infection) requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment;\n* Known history of HIV infection;\n* Other malignancies (except cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix) in the past 5 years;\n* Received live vaccine within 28 days before enrollment;\n* while participating in another therapeutic clinical trial.","ALL","18 Years","70 Years",{"count":73,"type":74},93,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)",[80],"Immunotherapy Esophagus Cancer","2024-02-04",{"date":83,"type":84},"2024-02-07","ACTUAL",{"date":86,"type":84},"2022-05-31",{"date":88,"type":74},"2027-05-31",{"name":5,"class":6},1]